University of Cincinnati Cancer Institute | Strategic Alliance Partners

Latest from University of Cincinnati Cancer Institute


Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer

September 07, 2020

In our exclusive interview, Thomas Herzog, MD, and Kathleen Moore, MD, reviewed the topline results of the 4 positive PARP inhibitor trials in the frontline maintenance setting and provided perspective on the potential applications of these data to clinical practice.

x